Amanat Acquisition Corp. quarterly report, Q3 FY2026

Amanat Acquisition Corp. — Form 10-Q Summary

Reporting period: Quarter ended September 30, 2026; filed November 13, 2026. Amanat is a Cayman Islands blank-check company and shell company formed to pursue a business combination. It had not begun operating or generating revenue as of quarter-end. The financial statements are unaudited.

Financial position and results

MetricAmount or status
RevenueNone; the company expects no operating revenue before a business combination.
Quarterly net loss$1,482,711 for the three months ended September 30, 2026.
Inception-to-date net loss$1,510,880 from January 13, 2026 through September 30, 2026.
Quarterly expenses$2,065,068 in formation, general and administrative costs and $112,050 in share-based compensation.
Quarterly non-operating income$681,207 in trust-account interest and $13,200 from the change in fair value of the expired over-allotment option liability.
Cash outside trust$1,080,559 at September 30, 2026; no cash equivalents.
Trust assets$75,971,231, including $971,231 of interest earned since inception; held in cash and U.S. Treasury securities.
Working capital$909,965.
Liabilities$4,161,529 total: $329,982 current, $1,581,547 deferred professional fees, and $2,250,000 deferred underwriting fees. No working capital loans were outstanding.
Cash flowNet cash used in operating activities was $739,666 from inception through September 30; financing activities provided $76,820,225. No quarterly cash-flow comparison is presented.
Margins and debtMargins are not meaningful because the company has no revenue. The filing reports no outstanding borrowings; deferred fees and other liabilities remain payable subject to their stated terms.

The public shares are classified as temporary equity and carried at a redemption value of approximately $10.13 per share. There is no prior-year comparable operating period in this filing; inception-to-date results should not be treated as a like-for-like prior-period comparison.

Material developments and outlook

  • On October 25, 2026, after quarter-end, Amanat signed a business combination agreement with Corxel Pharmaceuticals, Inc. and its sole stockholder. The proposed transaction implies a Corxel equity value of $200 million and is expected to close in the first half of 2027, subject to approvals and other conditions.
  • The agreement includes a $300 million PIPE commitment, subject to conditions and reduction mechanisms for investors that acquire and do not redeem public shares. A closing condition requires at least $200 million from specified available cash sources after redemptions, including PIPE proceeds and subject to the agreement’s stated limit on additional company cash.
  • The transaction requires, among other things, shareholder approvals, HSR waiting-period clearance, an effective registration/proxy statement, Nasdaq listing approval, and at least $5,000,001 in net tangible assets after the transaction. Public shareholders may redeem shares for their pro rata trust value.
  • Management states that available liquidity is insufficient to sustain operations for at least one year from issuance of the financial statements, raising substantial doubt about the company’s ability to continue as a going concern. The sponsor and its affiliates may lend funds but are not obligated to do so. If no business combination is completed within 24 months of the May 20, 2026 IPO closing, the company expects to cease operations and redeem public shares, subject to its governing documents and applicable law.
  • Significant transaction-related obligations include $1.58 million of deferred professional fees and a $2.25 million underwriting fee payable only upon completion of a business combination. The company also describes a $250,000 CEO transaction bonus upon completion and sponsor-paid officer and administrative compensation.

Risks, contingencies, and other disclosures

Completion of the Corxel transaction is not assured; it remains subject to approvals, regulatory clearance, financing and other closing conditions, and may be terminated in specified circumstances. The filing describes potential termination fees, including a $10 million adverse-recommendation fee, a superior-offer fee of the greater of $10 million or 1% of specified consideration subject to a $50 million cap, and reimbursement of certain regulatory costs up to $3 million. Sponsor indemnification for certain third-party claims against the trust has limitations.

The filing reports no legal proceedings and no material changes to the risk factors in the IPO prospectus. Management concluded disclosure controls were effective as of September 30, 2026, with no material change in internal control over financial reporting during the quarter.

Important facts for investors to verify

  • Progress toward shareholder and Corxel stockholder approvals, HSR clearance, registration-statement effectiveness, and the expected first-half 2027 closing.
  • Whether the $300 million PIPE remains available at closing, including any investor reductions, and whether the agreement’s minimum-cash and net-tangible-asset conditions can be met after redemptions.
  • Expected public-share redemptions and resulting trust cash, ownership dilution, and allocation of transaction consideration, including any pre-funded warrants and equity-plan shares.
  • How Amanat will fund ongoing expenses before closing given its limited cash outside the trust and management’s substantial-doubt going-concern disclosure.
  • Amounts and timing of deferred professional, underwriting, related-party, and transaction-compensation obligations, and the consequences if the transaction does not close before the completion deadline.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.